Precision Oncology and Basket Tumors
Research activity is centered on advanced cancers grouped by shared molecular features rather than tumor origin, with attention to basket tumor settings and clinically defined cancer subtypes.
- Advanced cancer populations
- Molecularly guided oncology
- Cross-tumor treatment selection
The clinical focus reflects interest in applying genomic profiling to identify patients whose tumors share actionable biological characteristics.
Homologous Recombination Deficiency and DNA Repair
Key research activity involves cancers associated with defects in homologous recombination and related DNA repair pathways, including tumors linked to inherited or acquired alterations in repair genes.
- HRD-associated malignancies
- Germline mutation–driven cancer
- Somatic tumor mutation
Interest extends to cancers defined by alterations in genes such as BRCA1, BRCA2, ATM, PALB2, and other homologous recombination genes.
PARP Inhibition in Oncology
The sponsor’s therapeutic interest includes PARP inhibitor research in advanced solid tumors, with emphasis on tumors carrying molecular signatures of HRD.
- Olaparib
- Targeted cancer therapy
- Response rate and response duration
This area connects treatment evaluation with biomarker-defined oncology, particularly for patients whose cancers show susceptibility to DNA damage response targeting.
Genetic Testing and Biomarker-Defined Cancer Care
Clinical interest is closely tied to routine genetic panel testing in Belgian laboratories, supporting identification of eligible mutations across a defined set of HR genes.
- Inherited cancer predisposition
- Tumor biomarker selection
- Genotype-based eligibility
The research landscape includes both germline and somatic alterations, with attention to clinically relevant variants that inform oncology treatment pathways.
